Vincent O'Neill - Jun 14, 2024 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Executive Vice President, Chief of Product Development and Medical Officer
Signature
/s/ Richard Steinhart, as Attorney in Fact for Vincent O'Neill
Stock symbol
BTAI
Transactions as of
Jun 14, 2024
Transactions value $
-$199
Form type
4
Date filed
6/18/2024, 09:25 PM
Previous filing
Apr 8, 2024
Next filing
Sep 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +521 +16.5% 3.68K Jun 14, 2024 Direct F1
transaction BTAI Common Stock Sale -$199 -155 -4.21% $1.29 3.52K Jun 17, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -521 -12.5% $0.00 3.65K Jun 14, 2024 Common Stock 521 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
F3 On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Remarks:

Executive Vice President, Chief of Product Development and Medical Officer